Compared to CAF, CAFQ lowered plasma glucose, increased liver IRS‐1 mRNA expressions, increased pancreatic β‐cell insulin immunoreactivity, and lowered hepatocyte degeneration and microvesicular steatosis. This evidence concerns the gene IRS1 and steatosis.